Method of Delaying The Onset of Clinically Definite Multiple Sclerosis
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsYafit Stark, David Ladkani
Life of this patent
Estimating the term…
Abstract
A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.
Claims19
A method for reducing the frequency of relapses in a patient who experienced a single clinical attack consistent with multiple sclerosis and who has at least one lesion consistent with multiple sclerosis prior to development of clinically definite multiple sclerosis (CDMS), the method consisting essentially of periodically administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of glatiramer acetate therapeutically effective to increase the time to relapse in the patient.
A method for delaying onset of clinically definite multiple sclerosis in a patient presenting a first clinical event consistent with multiple sclerosis and at least one lesion consistent with multiple sclerosis comprising periodically administering to the patient as monotherapy a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of glatiramer acetate therapeutically effective to delay onset of clinically definite multiple sclerosis.
A method of treating a patient who has experienced a first clinical episode and has MRI features consistent with multiple sclerosis consisting essentially of subcutaneously administering once a day to the patient prior to conversion to clinically definite multiple sclerosis a pharmaceutical composition comprising mannitol and 20 mg of glatiramer acetate.
Dependencies are inferred from the claim text.